Prescribing Fluvoxamine

Why Fluvoxamine Still Has a Place

Most American prescribers have never actually started a patient on fluvoxamine. It was the first SSRI approved for OCD in the United States, it is a standard drug for obsessive-compulsive disorder in much of the world, and it has a useful pharmacologic quirk (potent, broad cytochrome P450 inhibition) that occasionally makes it the right drug rather than merely an available one. Yet it sits near the bottom of most clinicians' SSRI hierarchies, and for defensible reasons: it is a promiscuous enzyme inhibitor that complicates polypharmacy, it produces more GI upset than its peers, and it is among the worst SSRIs for discontinuation syndrome.

So it is not a first-line antidepressant, and this guide will not pretend otherwise, but it does a few specific jobs precisely.

For straightforward depression, escitalopram or sertraline will almost always be the better opening move, with cleaner interactions, an easier taper, and a gentler stomach. Reach for fluvoxamine when the indication is OCD, when a patient has responded to it before, or when you actually want its CYP1A2 inhibition working for you (the clozapine trick below). Everywhere else, it is a second- or third-string agent.

Part 1: Indications

FDA-Approved Uses

• Obsessive-compulsive disorder (OCD): the flagship indication, in adults and in children/adolescents ages 8 and up (the immediate-release form carries a pediatric OCD indication)

OCD is the only U.S. indication. Depression is an approved indication in other markets, including the UK, so U.S. use for depression is off-label. The controlled-release capsule (Luvox CR) was also FDA-approved for social anxiety disorder in 2008, but current generic extended-release labels list OCD only, so treat the SAD indication as label-dependent (see Part 3).

OCD

OCD is where fluvoxamine earns its keep. It is a well-established, effective SSRI for obsessions and compulsions, and it carries the same core caveats as every serotonergic drug in OCD:

• OCD frequently needs higher doses than depression, often toward the top of the range, 200 to 300 mg/day.
• OCD responds slowly: allow 8 to 12 weeks at an adequate dose before calling a trial a failure, versus 4 to 6 weeks in depression.
• Response is usually partial (a meaningful reduction in symptoms), not remission. A 25 to 35% Y-BOCS reduction counts as a real, worthwhile response in OCD; hold onto it.
• Pair it with exposure and response prevention (ERP). Medication plus ERP beats either alone; the drug lowers the temperature enough to make the therapy possible.

Major Depression

Effective, but unremarkable relative to the class, and it brings more GI upset and a harder taper than escitalopram or sertraline. In the head-to-head efficacy literature (the Cipriani network meta-analysis of 21 antidepressants), fluvoxamine sits in the middle of the pack on efficacy and toward the lower end on acceptability. There is rarely a positive reason to choose it for uncomplicated depression.

Anxiety-Spectrum Disorders

Fluvoxamine has real efficacy across the anxiety disorders: panic disorder, social anxiety disorder (branded Luvox CR was FDA-approved here in 2008, though current generic ER labels list OCD only), generalized anxiety, and PTSD are all reasonable off-label or on-label targets. In the panic-disorder network meta-analyses, fluvoxamine shows favorable efficacy but a higher adverse-effect burden than sertraline or escitalopram. That pattern recurs with this drug: it works, but its peers are more comfortable to take.

The Schizo-OCD Niche

OCD symptoms are common in schizophrenia, and fluvoxamine is effective for them, but here its enzyme inhibition becomes dangerous, raising clozapine and olanzapine levels. See the interactions and special-populations sections; in these patients escitalopram is often the safer OCD-directed choice even though it lacks an OCD indication.

The Clozapine Maneuver

Fluvoxamine's biggest liability, its potent CYP1A2 inhibition, can become an asset when you use it on purpose. See Part 7; it is one of the few times you reach for this drug because of its interactions rather than in spite of them.

Who Is a Good Candidate

• Patients with OCD, especially those who have responded to fluvoxamine before or failed a cleaner SSRI
• Patients on minimal concurrent medication (the fewer CYP substrates on board, the safer fluvoxamine gets)
• Patients for whom sexual dysfunction is a dealbreaker: fluvoxamine has the lowest rate of sexual side effects among SSRIs, a real and underused advantage
• Patients who need or want an SSRI and have a specific reason to avoid the alternatives

Who Is a Poor Candidate

• Anyone on complex polypharmacy, particularly with CYP1A2, CYP3A4, or CYP2C19 substrates on board (theophylline, tizanidine, clozapine, warfarin, many benzodiazepines): fluvoxamine is on the short list of antidepressants with the greatest potential for problematic drug interactions, alongside the MAOIs and paroxetine
• Smokers on clozapine or theophylline where enzyme dynamics are already unstable
• Patients with a history of severe SSRI discontinuation syndrome, or who are likely to stop abruptly or run out of medication
• Uncomplicated depression where a cleaner SSRI will do the same job more comfortably

Part 2: Before You Start: Workup

Fluvoxamine requires no routine laboratory monitoring, no ECG, and no drug levels for monotherapy in an otherwise healthy patient; it is an SSRI, not lithium. The workup is a medication reconciliation and a conversation.

Before You Write It

• Reconcile every medication and supplement, prescription and OTC. This is the non-negotiable step. Look specifically for CYP1A2 substrates (clozapine, olanzapine, theophylline, tizanidine, caffeine, duloxetine, ramelteon, agomelatine), CYP3A4 substrates (many benzodiazepines, buspirone, guanfacine, statins, some antipsychotics), CYP2C19 substrates, and warfarin. If the list is long, reconsider the drug.
• Screen for bipolarity before any antidepressant, since an SSRI can flip a susceptible patient into mania or mixed states.
• Ask about NSAIDs and anticoagulants: the SSRI-class GI-bleeding interaction applies (see below).
• In women of childbearing potential, take a reproductive history and discuss pregnancy planning.
• Set expectations: about a month to benefit in depression, longer in OCD; early GI side effects that usually fade; and, above all, the plan never to stop abruptly.

If you are adding fluvoxamine to clozapine or another CYP1A2-dependent drug, get a baseline level of that drug before you start (see Part 7). That is the one "lab" fluvoxamine sometimes demands, and it is about the other drug, not fluvoxamine.

Part 3: How to Start and Dose

Formulations

• Immediate-release tablets: 25, 50, and 100 mg. The inexpensive generic standard, and the only form that carries the pediatric OCD indication (ages 8–17).
• Controlled-release capsules (Luvox CR): 100 and 150 mg. Once-daily, smoother, and easier to hold at steady state; more expensive and often less available. Approved in adults only.

Immediate-release fluvoxamine has a short half-life (about 15 to 20 hours), shorter than most SSRIs, which is part of why it is dosed twice daily at higher totals and why it discontinues so harshly. The CR formulation smooths the peaks and troughs and makes true once-daily dosing possible.

Dosing by Indication

• OCD, adults, IR (FDA-approved): 50 mg at bedtime, titrate by 50 mg every 4–7 days as tolerated; totals above 100 mg/day are split into two doses with the larger portion at bedtime; usual effective range 200–300 mg/day; max 300 mg/day.
• OCD, adults, CR (FDA-approved): 100 mg once daily at bedtime, titrate by 50 mg at weekly intervals; range 100–300 mg/day; max 300 mg/day.
• OCD, children/adolescents 8–17, IR only (FDA-approved): 25 mg at bedtime, titrate by 25 mg every 4–7 days; split into two doses above 50 mg/day; max 200 mg/day for ages 8–11 and 300 mg/day for adolescents 12–17. Per the label, therapeutic effect in female children may be reached at lower doses.
• Social anxiety disorder, CR: Luvox CR was FDA-approved for social anxiety disorder in adults in 2008; current generic extended-release labels list OCD only, so treat this as label-dependent (effectively off-label on most present-day labels). Dose exactly as for OCD: 100 mg qhs, increase 50 mg weekly, max 300 mg/day.
• Depression (off-label in the U.S.; approved elsewhere): 50 mg at bedtime, titrate by 50 mg every 4–7 days; most patients respond at 100–200 mg/day; max 300 mg/day.
• Other anxiety (panic disorder, GAD, PTSD; off-label): start and titrate as for depression, aiming for response; OCD-range doses are often needed.

Starting Dose and Titration

• Start 50 mg at bedtime for adults (25 mg for older or hepatically impaired patients). Bedtime dosing helps with the early nausea and sedation.
• Titrate by 50 mg every 4 to 7 days for the IR tablet, or by 50 mg at weekly intervals for CR, as tolerated toward the therapeutic range.
• Once the IR total exceeds about 100 mg/day, split the dose twice daily; per the label, if the two doses are unequal, give the larger dose at bedtime. The short half-life makes once-daily dosing at high totals uneven.
• Usual therapeutic range: 100 to 300 mg/day. The FDA maximum is 300 mg/day for both IR and CR.
• Depression and general anxiety often respond in the 100 to 200 mg/day range; OCD frequently needs 200 to 300 mg/day.

Target Dose by Diagnosis

• OCD: aim high. Much of the benefit lives at 200 to 300 mg/day. Titrate up willingly and give it 8 to 12 weeks at an adequate dose before calling the trial a failure. Maximum 300 mg/day.
• Depression and anxiety (off-label in the U.S.): aim moderate. Most patients respond at 100 to 200 mg/day; benefits plateau and side effects climb past moderate doses, so don't reflexively push to the ceiling.
• Maintenance: once the patient is stable, hold the lowest dose that maintains response and periodically reassess the need to continue (per label). There is no separate lower "maintenance dose"; you simply settle at the lowest effective one.

Dose-response

Fluvoxamine was left out of the major SSRI dose-response meta-analyses, so its optimal-dose curve is less well characterized than sertraline's or escitalopram's. Apply the general SSRI principle, with a modification for OCD. For depression the class lesson holds: benefits plateau and side effects climb past moderate doses, so don't reflexively push to the ceiling. For OCD, much of the benefit lives at the higher end of the range, so titrate up more willingly and give it time.

Dose Adjustments and Special Populations

• Hepatic impairment: fluvoxamine clearance falls by roughly 30%; start at 25 mg and titrate slowly with careful monitoring, expecting higher plasma levels and more adverse effects at a given dose.
• Renal impairment: the label specifies no dose adjustment and pharmacokinetics are not dramatically altered, but caution and slower titration are prudent; fluvoxamine is not meaningfully removed by dialysis.
• Geriatric (age >65): clearance is reduced and steady-state levels run higher, so start at 25 mg and titrate slowly. Older adults also carry the highest risk of SSRI-induced hyponatremia/SIADH (see Part 4).
• Pediatric: only the IR tablet is FDA-approved (OCD, ages 8–17). Start 25 mg qhs, divide twice daily above 50 mg/day, and cap at 200 mg/day for ages 8–11 or 300 mg/day for adolescents 12–17; therapeutic effect in female children may be reached at lower doses. Luvox CR is not established in children.
• Pregnancy/lactation: not a dose-adjustment question but a use-or-not decision, individualized (see Part 8). No renal/hepatic-style reduction is defined.

Stopping and Switching

• Discontinuation: taper gradually; never stop abruptly. Fluvoxamine's short half-life makes its discontinuation syndrome (dizziness, "brain zaps," nausea, irritability, insomnia) among the more abrupt of the SSRIs. Step the dose down over weeks, slowing further near the end and whenever withdrawal symptoms appear (full protocol in Part 9).
• MAOI washout, both directions: allow at least 14 days after stopping an MAOI before starting fluvoxamine, and at least 14 days after stopping fluvoxamine before starting an MAOI, to avoid serotonin syndrome. The same 14-day caution applies around linezolid and IV methylene blue (reversible MAO inhibitors).
• Switching another SSRI/SNRI: because of the harsh discontinuation, cross-taper where feasible rather than stopping one drug and starting the other cold.
• IR ↔ CR: convert at the same total daily milligrams (both cap at 300 mg/day), consolidating to a single bedtime dose on CR.

Part 4: Monitoring

For monotherapy in a healthy patient, there is almost nothing to draw. Monitoring here means clinical follow-up and watching for interactions.

• Weeks 1 to 4: check in for early GI side effects (usually resolve by day 3 to 7), activation/insomnia, and, especially in patients under 25, suicidality (the SSRI black-box warning applies; risk is highest in the first 2 weeks and after dose changes).
• About 4 weeks: assess early response in depression/anxiety; even "slightly better" justifies continuing and titrating. In OCD, don't judge yet; give it to 8 to 12 weeks.
• Elderly / first 2 weeks: consider a sodium check if the patient is symptomatic (lethargy, confusion, nausea); SSRI-induced SIADH/hyponatremia is most common early and in older patients.
• Ongoing: track sexual function, weight, emotional blunting, and GI tolerability at routine visits.

The one situation that demands real monitoring is co-prescription with a narrow-therapeutic-index CYP substrate, above all clozapine. There, check the substrate's level before and after adding fluvoxamine, and follow it regularly. Fluvoxamine creates that obligation, but the drug you monitor is the other one.

Part 5: Side Effects and How to Manage Them

Fluvoxamine's side-effect profile is the ordinary SSRI menu with two differences: more GI upset than average and less sexual dysfunction than average. As with any SSRI, most early effects are transient and dose-related; manage them so the patient stays on long enough to benefit.

Gastrointestinal

GI upset is fluvoxamine's standout burden. It is among the top SSRIs for diarrhea (odds ratio about 2.3 in meta-analysis, in the same tier as sertraline), and nausea is common early.

• Start low, titrate slowly, and take with food (the single most effective nausea measure).
• Dose at bedtime so the peak passes during sleep.
• Nausea is usually an early, self-limiting effect (days to a couple of weeks); tell patients that in advance so they don't quit on day 3.
• For persistent nausea, ondansetron 4 mg PRN is a clean antiemetic (no tardive-dyskinesia risk); ginger is a benign OTC option.
• For diarrhea that doesn't settle, dose reduction or a switch may be needed, which is one of the more common reasons fluvoxamine gets abandoned.

Sexual Dysfunction: Fluvoxamine's Relative Advantage

SSRIs as a class cause sexual dysfunction in 50 to 70% of patients (decreased libido, delayed or absent orgasm, reduced genital sensation). Fluvoxamine has the lowest reported rate among the SSRIs. The effect is still there, as it is across the class, but the lower rate is a legitimate reason to choose fluvoxamine for a patient in whom sexual side effects are a dealbreaker and OCD/anxiety is the target.

• Lower the dose if efficacy allows.
• Weekend drug holidays (skip Friday/Saturday, resume Sunday) have open-label support and are feasible with fluvoxamine's short half-life, but only if the patient does not develop discontinuation symptoms across the skip and is not at risk of relapse. Given fluvoxamine's harsh discontinuation profile, many patients will feel worse from the holiday than from the side effect; use this cautiously here.
• Switch or augment (e.g., add bupropion) if the problem persists, though if you've reached for fluvoxamine specifically for its low sexual burden, a switch may be self-defeating.

Activation, Insomnia, and Anxiety

As with any SSRI, jitteriness, insomnia, or a transient increase in anxiety can occur, especially early. Start low, dose at bedtime, and reassure; benzodiazepine coverage for the first week or two is reasonable in a highly anxious patient, but prefer a glucuronidated benzodiazepine (lorazepam, oxazepam, temazepam), because fluvoxamine will raise the levels of CYP-metabolized benzos like alprazolam (see Part 7).

Emotional Blunting

Blunting of both positive and negative affect ("gray," "flat," "robotic") is a common SSRI effect that appears at ordinary therapeutic doses and looks dose-related. If it appears, lower the dose; if the therapeutic effect can't be preserved without blunting, the drug may not be right for that patient.

Weight and Metabolic

Weight change with fluvoxamine is modest and broadly in line with the SSRI class (roughly a quarter of patients gain some weight over time; mechanisms include appetite recovery). Manage with the usual diet/activity counseling; it is not a leading reason to avoid this drug.

Other

• Sweating, tremor, fatigue: usual mild SSRI effects; manage with timing and dose.
• Sedation: more prominent than with activating SSRIs; leverage it by dosing at night.
• Apathy / RLS: occasional SSRI-class effects; SSRI-induced restless legs can respond to a dopamine agonist (e.g., pramipexole) if troublesome.

Part 6: Toxicity, Bleeding, and the Boxed Warning

Overdose

Fluvoxamine, like the SSRIs generally, is relatively safe in overdose compared with TCAs, MAOIs, or lithium. Isolated SSRI overdose is rarely lethal; the dangerous scenarios are serotonin syndrome (usually from a serotonergic combination, not SSRI monotherapy) and QT/seizure effects at very large ingestions or in combination overdoses. Management is supportive and belongs in an emergency department, but the drug is not lethal in the way its narrow-window competitors are.

Serotonin Syndrome

Risk rises sharply when fluvoxamine is combined with other serotonergic agents: MAOIs (contraindicated), tramadol, linezolid, methylene blue, triptans, other antidepressants, St. John's wort. The picture is agitation, autonomic instability (tachycardia, hypertension, hyperthermia), and neuromuscular findings (hyperreflexia, clonus, rigidity, tremor). Discontinue the serotonergic agents and provide supportive care; it is usually reversible if caught early. The triptan risk, though widely feared, is very low in practice.

GI Bleeding

The SSRI-class bleeding warning applies to fluvoxamine. SSRIs impair platelet aggregation (platelets can't synthesize serotonin, so they depend on plasma uptake). This produces a real but modest bleeding signal.

• Roughly 1 extra GI bleed per about 8,000 prescriptions at baseline.
• An NSAID raises the combined risk to about 4 times baseline (pooled odds ratio 4.25, 95% CI 2.82 to 6.42, in a 2014 meta-analysis). Warfarin, clopidogrel, and antiplatelet agents also raise it.
• A proton-pump inhibitor (e.g., omeprazole) largely neutralizes the added GI-bleeding risk.

Practically: mention it to patients with a prior GI bleed, current NSAID/anticoagulant use, or upcoming surgery; co-prescribe a PPI when risk is high; and prefer acetaminophen over NSAIDs. Fluvoxamine's CYP inhibition can also raise warfarin levels, which compounds the bleeding risk; flag that double hit.

Hyponatremia / SIADH

An SSRI-class effect, most common in the first weeks and in the elderly. Symptoms are lethargy, confusion, nausea, and, in severe cases, seizures. Check a sodium in symptomatic or elderly patients; treat with fluid restriction (typically 1 to 1.5 L/day) and, if needed, discontinuation.

Part 7: Drug Interactions

This is the section that matters most for fluvoxamine. More than with any other SSRI, its identity is defined by cytochrome P450 inhibition, which is potent and broad, hitting a wide array of enzymes.

• CYP1A2, potent (the most characteristic; the basis of the clozapine effect and the caffeine/theophylline/tizanidine interactions)
• CYP2C19, potent
• CYP3A4, significant (with additional effects on 2C9 and others)

This breadth is why fluvoxamine is grouped with the MAOIs and paroxetine as the antidepressants with the greatest potential for problematic drug interactions. The clinical consequence is simple: fluvoxamine raises the levels of a long list of co-prescribed drugs, sometimes dramatically.

Clinically Important Interactions

Management Strategy

Before you start fluvoxamine, list every CYP1A2/2C19/3A4 substrate the patient takes, and either avoid the combination or plan to reduce and monitor that substrate. When in doubt on a polypharmacy patient, a cleaner SSRI (escitalopram, sertraline) spares you the entire problem.

Part 8: Special Populations

Pregnancy

Fluvoxamine is handled like the rest of the SSRI class. For SSRIs overall, the picture is a low absolute teratogenic risk, a small independent signal for perinatal complications and (in third-trimester exposure) a neonatal adaptation syndrome (jitteriness, tremor, feeding difficulty, respiratory distress) in a minority of exposed newborns, usually self-limited, and a debated, small PPHN association. Weigh that against the real fetal and maternal harm of untreated illness, much of it mediated behaviorally (missed prenatal care, substance use, poor nutrition).

In practice, individualize. For mild illness, non-pharmacologic management or a taper may be reasonable; for moderate-to-severe OCD/depression where the patient has responded specifically to fluvoxamine, continuing it is often the right call. Sertraline is the more commonly chosen SSRI in pregnancy given its extensive reproductive-safety data and low milk transfer, so if you are selecting an SSRI de novo in a pregnant patient, that is usually the better default. Coordinate with obstetrics, and watch the neonate near delivery.

Lactation

Fluvoxamine is excreted into breast milk in low amounts, and it is generally considered relatively compatible with breastfeeding, though the reproductive-safety database is smaller than for sertraline (the usual first choice in lactation). If a mother is already stable on fluvoxamine, continuing it while monitoring the infant for feeding, sedation, and irritability is reasonable.

Elderly (Age Over 65)

• Start low (25 mg), titrate slowly, expect a lower effective dose (reduced clearance).
• Higher hyponatremia/SIADH risk, especially in the first two weeks; check sodium if symptomatic.
• Higher fall and bleeding risk, and more concurrent medications, which magnifies the CYP-interaction hazard. Do a careful medication reconciliation.

Children and Adolescents

• Fluvoxamine IR is FDA-approved for OCD from age 8, one of its distinguishing features.
• Start 25 mg, titrate by 25 mg, usual range 50 to 200 mg/day; the maximum is 200 mg/day up to age 11 and the adult 300 mg/day in adolescents; divide BID above 50 mg.
• The black-box suicidality warning is most salient here; monitor closely early, and involve caregivers.

Renal and Hepatic Impairment

• Renal: SSRIs are minimally renally cleared; no major adjustment is generally required, though caution and slower titration are sensible in significant impairment.
• Hepatic: fluvoxamine is hepatically metabolized; start lower and titrate more slowly in liver disease, and expect reduced clearance.

Part 9: Discontinuation

Discontinuation brings dizziness, "brain zaps" (brief electric-shock sensations), nausea, flu-like malaise, irritability, insomnia, and rebound anxiety, typically within a day or two of a missed dose or an abrupt stop, because the drug clears so quickly.

How to Stop

• Taper slowly, slower than you would for sertraline or escitalopram. There is no fixed maximum-safe rate, but plan on weeks to months, not days, particularly after long or high-dose use.
• Go hyperbolic near the end: the smallest doses matter most; the last steps down should be the slowest and smallest. Use the 25 mg and 50 mg tablets (or a compounded liquid) to make fine reductions.
• If withdrawal emerges, slow down or step back up to the last tolerated dose and re-taper more gradually. This is expected and manageable, and it does not mean the taper has failed.
• For a taper that stays stuck, a pragmatic bridge is to cross over to fluoxetine (long half-life, self-tapering) and then discontinue that, a standard trick for the difficult short-half-life SSRIs.
• Educate on day one: never stop abruptly, don't run out, and call before discontinuing. Because fluvoxamine punishes even a single missed dose, adherence counseling is discontinuation prevention.

As for whether to stop at all: for episodic depression, consider a taper after about 6 to 12 months of sustained wellness; for OCD, which is typically chronic and relapsing, long-term continuation is often appropriate, and if the patient is well, there is frequently no reason to invite a difficult taper at all.

Part 10: Fluvoxamine vs the Alternatives

• vs Escitalopram / Sertraline (the preferred SSRIs): these "rise to the top" for a reason: cleaner interaction profiles, gentler discontinuation, and (for sertraline/escitalopram) strong tolerability. For uncomplicated depression or anxiety, choose one of them over fluvoxamine almost every time. Fluvoxamine wins only when its specific advantages apply: OCD, lowest sexual dysfunction, prior response, or a deliberate use of its CYP1A2 inhibition.
• vs Paroxetine: both are interaction-heavy and hard to discontinue, but paroxetine adds the worst sexual-dysfunction and anticholinergic/cognitive burden of the class. Between two problematic SSRIs, fluvoxamine at least offers low sexual side effects and a legitimate OCD pedigree. Neither should be a casual first pick.
• vs Fluoxetine: fluoxetine's long half-life makes it far easier to discontinue and forgiving of missed doses, the opposite of fluvoxamine. Fluoxetine is also a strong OCD agent. Fluvoxamine's edges are lower sexual dysfunction and its 1A2 inhibition; fluoxetine's are the smooth taper and a huge evidence base.
• vs Clomipramine / SNRIs in OCD: clomipramine is arguably the most potent single agent in OCD but carries TCA toxicity and side effects; SSRIs (including fluvoxamine) are safer first-line, with clomipramine held in reserve. Among SSRIs for OCD, fluvoxamine is a perfectly respectable choice: the class is roughly comparable, so tolerability and interactions decide.

Mechanism

Fluvoxamine is a selective serotonin reuptake inhibitor: it blocks the serotonin transporter (SERT), raising synaptic serotonin. As with all SSRIs, transporter blockade is immediate but clinical benefit takes about 4 weeks (longer in OCD); the lag is attributed to gradual desensitization of serotonin autoreceptors and downstream BDNF-mediated neuroplastic change rather than the acute rise in serotonin itself.

Two pharmacologic footnotes set it apart. First, its potent, broad cytochrome P450 inhibition (especially CYP1A2) defines the drug's clinical personality far more than any receptor selectivity does. Second, fluvoxamine is a potent agonist at the sigma-1 receptor, a chaperone protein implicated in ER stress and inflammation; this is the pharmacologic rationale behind its investigational use in inflammatory conditions, and a reminder that "SSRI" undersells what this molecule actually does.

The Bedside Cheat Sheet